Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Oct 3:8:e48120.
doi: 10.7554/eLife.48120.

Cryo-EM structures of the human glutamine transporter SLC1A5 (ASCT2) in the outward-facing conformation

Affiliations

Cryo-EM structures of the human glutamine transporter SLC1A5 (ASCT2) in the outward-facing conformation

Xiaodi Yu et al. Elife. .

Abstract

Alanine-serine-cysteine transporter 2 (ASCT2, SLC1A5) is the primary transporter of glutamine in cancer cells and regulates the mTORC1 signaling pathway. The SLC1A5 function involves finely tuned orchestration of two domain movements that include the substrate-binding transport domain and the scaffold domain. Here, we present cryo-EM structures of human SLC1A5 and its complex with the substrate, L-glutamine in an outward-facing conformation. These structures reveal insights into the conformation of the critical ECL2a loop which connects the two domains, thus allowing rigid body movement of the transport domain throughout the transport cycle. Furthermore, the structures provide new insights into substrate recognition, which involves conformational changes in the HP2 loop. A putative cholesterol binding site was observed near the domain interface in the outward-facing state. Comparison with the previously determined inward-facing structure of SCL1A5 provides a basis for a more integrated understanding of substrate recognition and transport mechanism in the SLC1 family.

Keywords: ASCT2; SLC1A5; cryo-EM; glutamine transporter; human; molecular biophysics; outward-facing conformation; solute carrier; structural biology.

PubMed Disclaimer

Conflict of interest statement

XY, OP, PB, TS, TM, DD, YC, GW, XQ, JC, SH is affiliated with Pfizer Inc. The author has no other competing interests to declare. YD, EC No competing interests declared

Figures

Figure 1.
Figure 1.. Cryo-EM structure of human SLC1A5.
(a) A density map of SLC1A5 homotrimer viewed from the side of the membrane (left) and the extracellular face (right) highlighting the scaffold domain (green), transport domain (navy), ECL2 (red) and N-acetyl-D-glucosamine (NAG, in orange). The density assigned to CHS is colored in magenta. (b) Micelle/membrane and trimerization interfaces are highlighted in gray and wheat, respectively. Interactions between transport and scaffold domains are illustrated with lines. (c) A schematic representation of the domains present in human SLC1A5. The N-linked glycosylation sites are indicated by orange circle. Dashed lines represent residues disordered in the structure.
Figure 1—figure supplement 1.
Figure 1—figure supplement 1.. SLC1A5 protein purification, functional assays in cells and proteoliposomes and negative staining.
(a) Uptake of [14C]-glutamine in HAP1 SLC1A5KO cells or SLC1A5KO cells transiently transfected with pcDNA3 vector containing the indicated sequence in the presence (solid bar) or absence (open bar) of sodium chloride. (b), (c) Uptake of [3H]-L-glutamine by purified SLC1A5 reconstituted in proteoliposomes. Transport was started by the addition of 50 μM L-glutamine/[3H]-L-glutamine (100 dpm/pmole) to SLC1A5 proteoliposomes in the presence (▪) or absence (□) of 100 mM external sodium chloride. (b) Internal proteoliposome buffer contained 10 mM glutamine and uptake was measured at the indicated times. The experiment was performed with triplicates at each time point; error bars represent standard deviation. (c) Internal buffer contained either low internal glutamine (0 mM or 0.1 mM) or 10 mM glutamine and uptake was measured at 90 min. The graphs are means of three independent experiments performed in triplicate. Error bars represent the s.e.m. Similarly prepared SLC1A5 in proteoliposomes showed [3H]-glutamine efflux in the presence of external (assay buffer) glutamate and NaCl (Oppedisano et al., 2007). (d), (e) Size-exclusion chromatography (Superose 6 10/300 Increase filtration column) of SLC1A5 and its complex with cKM4012 (Fab). The peak fraction was examined by SDS-polyacrylamide gel electrophoresis (SDS-PAGE). (f) Raw micrograph of SLC1A5-cKM4012 (Fab) complex by negative-stain electron microscopy. (g) 2D-class averages of particles from negative-stain electron microscopy of SLC1A5-cKM4012 (Fab) complex. Signals corresponding to the SLC1A5 and Fabs are highlighted.
Figure 1—figure supplement 2.
Figure 1—figure supplement 2.. Cryo-EM analysis of SLC1A5-cKM4012 (Fab) complex.
(a) Flow chart of the cryo-EM data processing procedure. Details can be found in the Materials and methods. (b) A representative cryo-EM micrograph. (c) Local resolution of the map estimated using the ResMap program and colored as indicated. (d) Angular orientation distribution of the particles used in the final reconstruction. The particle distribution is indicated by different color shades. (e) Fourier shell correlation (FSC) curve of the structure with FSC as a function of resolution using cisTEM output. The resolution is ~3.5 Å at the FSC cutoff of 0.143. A thin vertical line indicates that only spatial frequencies to 1/ (7.8 Å) are used to determine particle alignment parameters during refinement in cisTEM.
Figure 1—figure supplement 3.
Figure 1—figure supplement 3.. Cryo-EM analysis of SLC1A5-cKM4012 (Fab) complex in the presence of L-glutamine.
(a) Flow chart of the cryo-EM data processing procedure. Details can be found in the Materials and methods. (b) A representative cryo-EM micrograph. (c) Local resolution of the map estimated using the ResMap program and colored as indicated. (d) Angular orientation distribution of the particles used in the final reconstruction. The particle distribution is indicated by different color shades. (e) Fourier shell correlation (FSC) curve of the structure with FSC as a function of resolution using cisTEM output. The resolution is ~3.8 Å at the FSC cutoff of 0.143. A thin vertical line indicates that only spatial frequencies to 1/ (7.8 Å) are used to determine particle alignment parameters during refinement in cisTEM.
Figure 1—figure supplement 4.
Figure 1—figure supplement 4.. Cryo-EM densities of the eight transmembrane helices with ECL loops of SLC1A5-cKM4012 (Fab).
(a) Cryo-EM density is sharpened with a negative b-factor 15 Å2 and displayed at the contour level 8σ for the transmembrane helixes and loops regions, except for the ECL2a, and b regions at 5.6σ and 4σ respectively. The atomic model with side chains are shown as sticks. The segments are labeled and colored as in Figure 1c. (b) Model validation. Comparison of the FSC curves between model and half map 1 (work), model and half map 2 (free), and model and full map are plotted in red, green and blue, respectively.
Figure 1—figure supplement 5.
Figure 1—figure supplement 5.. Sequence alignment of human SLC1 transporters and two prokaryotic homologues.
The secondary structural features are presented according to the human SLC1A5 cryo-EM structures in this study. The color-coding scheme is the same as in Figure 1d. The secondary element changes on TM3 and TM6 upon outward- and inward-transitions are indicated. Conserved residues are highlighted and filled in red. Residues involved in the substrate binding and the neighboring pocket for SLC1A5 are boxed in cyan and green, respectively. Key residues for substrate specificity are indicated by black filled circles. The residues involved in inter-protomer interactions are boxed in black. Residues from Zone two and their interacting residues from the scaffold domain in the inward-facing state are highlighted using blue and green ▼, respectively. Residues from Zone one and their interacting residues from the scaffold domain in the outward-facing state are highlighted using blue and green ▲, respectively. Shared residues from the transport and scaffold domains during conformational changes are highlighted using blue and green , respectively. The conserved residues are filled in orange. The N-linked glycosylation sites are indicated by orange open circles. Dashed lines represent the sequences which are not observed from cryo-EM density.
Figure 2.
Figure 2.. Structural comparison between outward- and inward-facing states of SLC1A5.
(a and b) Structure of the SLC1A5 monomer viewed from the side of the membrane highlighting TM6 and TM3, respectively. Transport domains are represented as molecular surfaces and colored in navy. Scaffold domains are in green. TM6 and TM3 are colored in orange in the outward-facing state (left) and pink in the inward-facing state (middle, PDB: 6GCT). Overlay of scaffold domains of inward- and outward-facing states highlighting TM3 and TM6 (right). The glutamine substrate is shown as a red ball. (c) Superposition of the transport domains of SLC1A5 in the outward- and inward-facing (PDB: 6GCT) states (left). The conformational changes of TM6 (middle) and TM3 (right) between the outward-facing and inward-facing states are highlighted. (d) Transport domains of SLC1A5 in an outward-facing state (left) and a cross-linked GltPH in inward-facing state (middle, PDB:3KBC) viewed from the extracellular face. The SLC1A5 transport domain in the outward-facing conformation serving as the reference is shown in molecular surface. The conformational changes of ECL2a between the outward- (in red) and inward-facing (in cyan) states are highlighted (right).
Figure 3.
Figure 3.. The substrate, L-glutamine-bound SLC1A5 structure.
(a) Conformational change for the HP2 upon binding of L-glutamine in the outward-facing state of SLC1A5. The unliganded structure is shown in gray and the L-glutamine-bound structure is in navy. EM density over the ligand is shown as a blue mesh. (b and c) Zoomed in views of the substrate binding sites of the outward-facing and inward-facing states (PDB:6GCT) of SLC1A5, respectively. (d) Interaction of L-Asp in the outward-facing state of SLC1A3 (PDB code: 5LLU). Critical side chains are labeled (stick representation) with hydrogen bonds (red dashed lines). Molecular surface in the substrate binding sites are in pink.
Figure 3—figure supplement 1.
Figure 3—figure supplement 1.. The extracted ion chromatograph (above) and the mass spectrum (below) for CHS is shown in negative ion mode.
CHS is measured with a three ppm accuracy in the SLC1A5 sample. The exact mass, elution time, and fragmentation pattern are validated against a commercially bought standard (Sigma-Aldrich, St. Louis).
Figure 3—figure supplement 2.
Figure 3—figure supplement 2.. Potential CHS interaction in outward- and inward-facing conformation of SLC1A5.
(a) Elongated densities, shown as blue mesh (~6σ), are observed between two protomers of SLC1A5 trimer in both the outward- and inward-facing (PDB: 6GCT) cryo-EM structures. (b) A density is embedded in the cavity enclosed by two SLC1A5 protomers (one in green, and the other in gray). One CHS molecule, shown as magenta sticks, can be docked into this density. TM4a and TM4c provide the primary accommodation site for the CHS molecule. The contour and composition of the cavity define the orientation of the bound CHS. Note that a cholesterol molecule can be accommodated in the hydrophobic pocket the same as CHS.
Figure 3—figure supplement 3.
Figure 3—figure supplement 3.. Cryo-EM densities of the substrate and putative CHS binding sites of SLC1A5, at the contour level 6σ.
(a) Cryo-EM densities of the substrate-binding site with (upper panel) or without (lower panel) Gln substrate. (b) Cryo-EM densities of the putative CHS binding site with (upper panel) or without (lower panel) Gln substrate. The backbone of the models is shown. The Gln substrate and CHS are shown as sticks. The side chains of Y276 and W272 are shown as a reference.
Figure 3—figure supplement 4.
Figure 3—figure supplement 4.. Selective examples of allosteric druggable pockets at the lipid-exposed surface near the intracellular part of membrane proteins.
Different protomers are shown in surface with different gray scale. Each ligand is colored in yellow ball-and-sticks. Examples of allosteric sites include the RTX agonist binding site in the capsaicin and heat-activated cation channel TRPV1 (Gao et al., 2016), the extra-helical NDT9513727 antagonist binding site in the complement C5a receptor (Robertson et al., 2018), the agoPAM binding site in the free fatty acid receptor GPR40 (Lu et al., 2017) and a negative allosteric modulator binding site in the glucagon receptor (Zhang et al., 2017).
Figure 4.
Figure 4.. Schematic representation of conformational changes in SLC1A5 during substrate transport.
(a) In the outward-facing state (top), the Zone two from the transport domain interacts with the scaffold domain, with the Zone one partially occupied by the ECL2a. Two different poses of the ECL2a were observed (shown in red and dark gray lines): one is situated at the side of the transport domain (red line); the other is crossing over the crests of ECL4 and ECL5 (dark gray line). In the inward-facing state (bottom), the ECL2a has to be repositioned, releasing the Zone one to interact with the scaffold domain. Residues from Zone one and Zone two are highlighted (Figure 1—figure supplement 5). (b) The inherent plasticity around the TM2-3 loop, ECL3, TM3, and TM6 regions (highlighted in dash lines) allows the transitions between the outward-facing (top) and inward-facing states (bottom). The relative position of transport domain in the outward-facing state is highlighted in dash (bottom panel in b). The regions of SLC1A5 are colored based on the Figure 1a. The light gray line depicts membrane boundary.

References

    1. Adams PD, Afonine PV, Bunkóczi G, Chen VB, Davis IW, Echols N, Headd JJ, Hung LW, Kapral GJ, Grosse-Kunstleve RW, McCoy AJ, Moriarty NW, Oeffner R, Read RJ, Richardson DC, Richardson JS, Terwilliger TC, Zwart PH. PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallographica Section D Biological Crystallography. 2010;66:213–221. doi: 10.1107/S0907444909052925. - DOI - PMC - PubMed
    1. Akyuz N, Georgieva ER, Zhou Z, Stolzenberg S, Cuendet MA, Khelashvili G, Altman RB, Terry DS, Freed JH, Weinstein H, Boudker O, Blanchard SC. Transport domain unlocking sets the uptake rate of an aspartate transporter. Nature. 2015;518:68–73. doi: 10.1038/nature14158. - DOI - PMC - PubMed
    1. Arnold K, Bordoli L, Kopp J, Schwede T. The SWISS-MODEL workspace: a web-based environment for protein structure homology modelling. Bioinformatics. 2006;22:195–201. doi: 10.1093/bioinformatics/bti770. - DOI - PubMed
    1. Barad BA, Echols N, Wang RY, Cheng Y, DiMaio F, Adams PD, Fraser JS. EMRinger: side chain-directed model and map validation for 3D cryo-electron microscopy. Nature Methods. 2015;12:943–946. doi: 10.1038/nmeth.3541. - DOI - PMC - PubMed
    1. Boudker O, Ryan RM, Yernool D, Shimamoto K, Gouaux E. Coupling substrate and ion binding to extracellular gate of a sodium-dependent aspartate transporter. Nature. 2007;445:387–393. doi: 10.1038/nature05455. - DOI - PubMed

Publication types

MeSH terms